lu codes
Source: ODB Formulary/CDI, edition 43 (effective 2026-04-28). Checked weekly for updates. Unofficial search tool.
/
showing 10 of 12 drugs (19 codes)
FORMOTEROL FUMARATE, FORMOTEROL FUMARATE DIHYDRATE, SALMETEROL XINAFOATE Foradil, Oxeze Turbuhaler, SereVent Diskus
For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.
Indefinite
This drug is not for relief of acute symptoms.
sympathomimetic (adrenergic) agents
IPRATROPIUM BROMIDE, IPRATROPIUM BROMIDE/SALBUTAMOL Atrovent, AA-Ipravent, Novo-Ipramide, PMS-Ipratropium, Combivent UDV, Teva-Combo Sterinebs +2 more
Patients who have a tracheostomy;
Indefinite
Patients with cystic fibrosis in whom nebulizer therapy is indicated;
Indefinite
Patients with severe mental or physical disabilities;
Indefinite
Patients who have previously used nebulizer therapy within the last 12 month period.
Indefinite
parasympatholytic (cholinergic blocking) agents
IPRATROPIUM BROMIDE, SALBUTAMOL Atrovent UDV, PMS-Ipratropium, Ratio-Ipratropium UDV, Teva-Ipratropium Sterinebs, Teva-Salbutamol Sterinebs P.F., PMS-Salbutamol +1 more
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have a tracheostomy;
Indefinite
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and be patients with cystic fibrosis in whom nebulizer therapy is indicated;.
Indefinite
Individuals must have a known hypersensitivity to the preservative in the bulk solution, and have severe mental or physical disabilities;
Indefinite
Patients who have previously used nebulizer therapy within the last 12 month period.
Indefinite
parasympatholytic (cholinergic blocking) agents
BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE, FLUTICASONE FUROATE & VILANTEROL, MOMETASONE FUROATE & FORMOTEROL FUMARATE DIHYDRATE, SALMETEROL XINAFOATE & FLUTICASONE PROPIONATE Symbicort 100 Turbuhaler, Symbicort 200 Turbuhaler, Breo Ellipta, Zenhale, Advair 125, Advair 250 +3 more
For the treatment of asthma in patients who are using optimum anti-inflammatory treatment and are still experiencing breakthrough symptoms.
Indefinite
sympathomimetic (adrenergic) agents
DONEPEZIL HCL, GALANTAMINE HYDROBROMIDE, RIVASTIGMINE Aricept, PMS-Donepezil, Sandoz Donepezil, Teva-Donepezil, Apo-Donepezil, Ran-Donepezil +26 more
Initial Trial: For patients with mild to moderate Alzheimer's Disease (Mini-Mental State Exam [MMSE] 10-26). Patients will be reimbursed for a period of up to 3 months after which continued treatment must be reassessed.
1 year
Network note: Maximum duration 3 months.
Continuation: Further reimbursement will be made available to those patients whose disease has not progressed/deteriorated while on this drug. Patients must continue to have a MMSE score of 10-26.
1 year
parasympathomimetic (cholinergic) agents
SALMETEROL XINAFOATE SereVent Diskus
For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.
Indefinite
sympathomimetic (adrenergic) agents
INDACATEROL Onbrez Breezhaler
For patients with moderate to severe COPD with persistent respiratory symptoms despite an adequate trial of, or an intolerance to, a regularly scheduled short-acting bronchodilator AND a long-acting anticholinergic.
Indefinite
Note: The dose of Onbrez Breezhaler should not exceed 75mcg per day.
sympathomimetic (adrenergic) agents
FLUTICASONE FUROATE & VILANTEROL Breo Ellipta
For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have a history of exacerbations and have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).
Indefinite
COPD disease severity is based on spirometry, symptoms and disability (see classification below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent
sympathomimetic (adrenergic) agents
TIOTROPIUM BROMIDE MONOHYDRATE & OLODATEROL HYDROCHLORIDE, ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE, INDACATEROL & GLYCOPYRRONIUM, UMECLIDINIUM & VILANTEROL Inspiolto Respimat, Duaklir Genuair, Ultibro Breezhaler, Anoro Ellipta
For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)).
Indefinite
COPD disease severity is based on spirometry, symptoms and disability (see classification tables below).
Classification
COPD Stages - Symptoms and disability:
Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill.
Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level
Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure
Classification by impairment of lung function:
COPD stage and spirometry (post bronchodilator) FEV1 predicted:
Mild: Greater than or equal to 80 percent
Moderate: 50 to 79 percent
Severe: 30 to 49 percent
Very severe: Less than 30 percent
parasympatholytic (cholinergic blocking) agents antimuscarinics/antispasmodics
HYOSCINE BUTYLBROMIDE, SCOPOLAMINE HYDROBROMIDE, GLYCOPYRROLATE, PHENOBARBITAL, PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, DIAZEPAM, LORAZEPAM, FUROSEMIDE, DIMENHYDRINATE, METOCLOPRAMIDE HCL Buscopan, Accel-Hyoscine, Scopolamine Hydrobromide Injection, Sandoz Glycopyrrolate, Robinul, Glycopyrrolate Injection +12 more
For the management of patients receiving palliative care*.
1 year
*The patient must have a progressive life-limiting illness and require this medication for palliative purposes.
parasympatholytic (cholinergic blocking) agents
No matching LU codes found.